IBRX · CIK 0001326110 · FY2025 live · 2025-12-31
ImmunityBio, Inc.
View as
Model
Classic Z
FY2025
−11.55
Zone
Distress
Prior
—
Market DD
—
1y PD
—
−11.55
Z″ −24.85
Score −11.55 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.501.2 × = 0.61X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
−7.431.4 × = −10.40X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
−0.513.3 × = −1.68X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
−0.500.6 × = −0.30X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
0.231 × = 0.23
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings rather than invent a series.
Overview
rule-v1
ImmunityBio, Inc. is on classic Z at −11.55 (distress) for FY2025, from an SEC 10-K. Retained earnings / assets is the line that sets the print. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers; buybacks can send retained earnings negative at otherwise healthy issuers, and X4 is book equity, not market cap.
Book screen Distress; market PD —. Tape not priced — not a single default call.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 14th percentile in Healthcare.
- MCRBDistressSeres Therapeutics, Inc.−11.55
- FEMYDistressFEMASYS INC−11.56
- EOCNDistressGalmed Pharmaceuticals Ltd.−11.50
- INMBDistressInmune Bio, Inc.−11.48
- ALGSDistressAligos Therapeutics, Inc.−11.66
- HOWLDistressWerewolf Therapeutics, Inc.−11.75
- HUMADistressHumacyte, Inc.−11.27
- BHVNDistressBiohaven Ltd.−11.16
KPI widgets
Current assets
$315M
Total assets
$502M
Current liabilities
$62M
Total liabilities
$1.0B
Working capital
$253M
Retained earnings
−$3.7B
EBIT
−$256M
Total sales
$113M
Book equity
−$500M
Accession 0001326110-26-000030. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-12-31). Classic Z is the live score. View as does not rewrite the live rank. X4 is book equity. Pulled 12 Sept 2026.